Pharmexa initiates phase I study of two HIV vaccines  

2006.02.02
Danish biotech company Pharmexa is initiating a phase I trial in collaboration with HIV Vaccine Trials Network to test the safety of two HIV vaccines developed by Pharmexa-Epimmune, a US subsidiary of Pharmexa

Danish biotech company Pharmexa is initiating a phase I trial in collaboration with HIV Vaccine Trials Network to test the safety of two HIV vaccines developed by Pharmexa-Epimmune, a US subsidiary of Pharmexa. The trial will test whether the two vaccines, which are designed to be used in combination, are well tolerated, and whether they cause appropriate immune responses in humans.

The first vaccine EP HIV-1090, is a DNA plasmid which has previously been tested in humans and shown to be safe. The second vaccine EP-1043, a recombinant protein, will be tested in humans for the first time. The phase I trial will include around 120 people and will be conducted in the US and Peru.

UNAIDS figures show that more than 40 million people worldwide are HIV positive. Each day an estimated 13,000 new HIV infections occur, of which 95% are in developing countries. In 2005, approx. 3.1 million people died from AIDS, the highest figure recorded. The news was reported by BiotechDenmark and on the Pharmexa website.

Pharmexa is based in Hørsholm Science Park north of Copenhagen. The company focuses on development of new immunotherapy drugs for the treatment of cancer and inflammatory diseases. Pharmexa has several technology platforms in recombinant protein vaccines (the AutoVac technology platform), DNA vaccines and peptide vaccines as well as a promising pipeline of drug candidates. Pharmexa has been listed on the Copenhagen Stock Exchange since 2000.

Link > Pharmexa 

Next step

Explore business cases

Please contact me

Name
Company
E-mail
Phone
How can we help you?

IDK
We use cookies to make the website perform optimally. You accept cookies by closing the box or continuing to use the website. Click here to read more about cookies. ×